Beyond Air Announces Expected Revenue of $2.3M for Q3 2026
Beyond Air (XAIR), a commercial-stage medical device and biopharmaceutical company, announced on Thursday that it expects to report unaudited revenue of $2.3 million for the quarter ended September 30, 2026. This represents a year-on-year increase of 27%, signaling continued growth in its operations. The projected quarterly revenue highlights Beyond Air's progress as it continues to scale its commercial activities and expand market presence across medical device and biopharmaceutical offerings.
Tickers: $XAIR
Topics: financial performance revenue